References

Abiraterone and increased survival in metastatic prostate cancer

10.1056/nejmoa1014618 · 2011 · External reference

Increased survival with enzalutamide in prostate cancer after chemotherapy

10.1056/nejmoa1207506 · 2012 · External reference

Apalutamide treatment and metastasis-free survival in prostate cancer

10.1056/nejmoa1715546 · 2018 · External reference

Darolutamide in nonmetastatic, castration-resistant prostate cancer

10.1056/nejmoa1815671 · 2019 · External reference

Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): A randomised, open-label, phase 3 trial

10.1016/s1470-2045(22)00507-1 · 2022 · External reference

Olaparib for metastatic castration-resistant prostate cancer

10.1056/nejmoa1911440 · 2020 · External reference

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: Second interim analysis of the randomized phase III MAGNITUDE trial

10.1016/j.annonc.2023.06.009 · 2023 · External reference

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): A randomised, placebo-controlled, phase 3 trial

10.1016/s0140-6736(23)01055-3 · 2023 · External reference

Rucaparib or physician’s choice in metastatic prostate cancer

10.1056/nejmoa2214676 · 2023 · External reference

CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

10.1200/jco.2024.42.4_suppl.18 · 2024 · External reference

PARP and CDK4/6 inhibitor combination therapy induces apoptosis and suppresses neuroendocrine differentiation in prostate cancer

10.1158/1535-7163.mct-20-0848 · 2021 · External reference

Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: A randomized, placebo-controlled phase II trial (ProCAID)

10.1200/jco.20.01576 · 2021 · External reference

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): A multicentre, randomised, double-blind, phase 3 trial

10.1016/s0140-6736(21)00580-8 · 2021 · External reference

An operational definition of epigenetics

10.1101/gad.1787609 · 2009 · External reference

LBA69 Prostate cancer efficacy results from a randomised phase III evaluation of transdermal oestradiol (tE2) versus luteinising hormone releasing hormone agonists (LHRHa) for androgen suppression in non-metastatic (M0) prostate cancer

10.1016/j.annonc.2024.08.2312 · 2024 · External reference

Treatment of mCRPC in the AR-axis-targeted therapy-resistant state

10.1093/annonc/mdv267 · 2015 · External reference

The role of CYP17A1 in prostate cancer development: Structure, function, mechanism of action, genetic variations and its inhibition

10.4149/gpb_2017024 · 2017 · External reference

The role of ketoconazole in current prostate cancer care

10.1038/s41585-018-0077-y · 2018 · External reference

Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5

10.1200/jco.2014.56.5119 · 2015 · External reference

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

10.1016/s1470-2045(12)70379-0 · 2012 · External reference

Abiraterone in metastatic prostate cancer without previous chemotherapy

10.1056/nejmoa1209096 · 2013 · External reference

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

10.1016/s1470-2045(14)71205-7 · 2015 · External reference

Abiraterone for prostate cancer not previously treated with hormone therapy

10.1056/nejmoa1702900 · 2017 · External reference

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial

10.1016/s1470-2045(19)30082-8 · 2019 · External reference

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

10.1016/s0140-6736(22)00367-1 · 2022 · External reference

Enzalutamide in metastatic prostate cancer before chemotherapy

10.1056/nejmoa1405095 · 2014 · External reference

Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer

10.1056/nejmoa1800536 · 2018 · External reference

Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer

10.1056/nejmoa2003892 · 2020 · External reference

ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer

10.1200/jco.19.00799 · 2019 · External reference

LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA)+ androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

10.1016/j.annonc.2021.08.2101 · 2021 · External reference

Enzalutamide with standard first-line therapy in metastatic prostate cancer

10.1056/nejmoa1903835 · 2019 · External reference

Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC)

10.1200/jco.2022.40.17_suppl.lba5004 · 2022 · External reference

Improved outcomes with enzalutamide in biochemically recurrent prostate cancer

10.1056/nejmoa2303974 · 2023 · External reference

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial

10.1016/s1470-2045(18)30456-x · 2018 · External reference

Apalutamide for metastatic, castration-sensitive prostate cancer

10.1056/nejmoa1903307 · 2019 · External reference

Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study

10.1200/jco.20.03488 · 2021 · External reference

Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide

10.1056/nejmoa2001342 · 2020 · External reference

Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

10.1056/nejmoa2119115 · 2022 · External reference

Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial

10.1200/jco.23.00041 · 2023 · External reference

LBA68 Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial

10.1016/j.annonc.2024.08.2311 · 2024 · External reference

Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: A retrospective cohort study

10.1038/s41391-023-00757-0 · 2023 · External reference

Highly potent and selective nonsteroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases

10.1021/jm400484p · 2013 · External reference

599P A phase I dose-escalation study of LAE001/prednisone plus afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment

10.1016/j.annonc.2021.08.1112 · 2021 · External reference

1817P A phase I/II efficacy and safety study of LAE001/prednisone and afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following 1-3 lines of standard of care

10.1016/j.annonc.2023.09.2765 · 2023 · External reference

First-in-class small molecule to inhibit CYP11A1 and steroid hormone biosynthesis

10.1158/1535-7163.mct-22-0115 · 2022 · External reference

Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES)

10.1200/jco.2022.40.6_suppl.018 · 2022 · External reference

1364MO Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients

10.1016/j.annonc.2022.07.1496 · 2022 · External reference

1605P Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results

10.1016/j.annonc.2024.08.1686 · 2024 · External reference

Targeted inhibition of CYP11A1 in castration-resistant prostate cancer

2024 · External reference

MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results

10.1200/jco.2024.42.4_suppl.159 · 2024 · External reference

ODM-204, a novel dual inhibitor of CYP17A1 and androgen receptor: Early results from phase I dose escalation in men with castration-resistant prostate cancer

10.1016/j.euf.2018.08.022 · 2020 · External reference

Novel dual inhibitors of AR/AR variants and AKR1C3: Preclinical activities for advanced prostate cancer therapy

2024 · External reference

Targeting the N-terminal domain of the androgen receptor: A new approach for the treatment of advanced prostate cancer

10.1634/theoncologist.2016-0161 · 2016 · External reference

Intrinsic disorder in the androgen receptor: Identification, characterisation and drugability

10.1039/c1mb05249g · 2012 · External reference

EPI-001, A compound active against castration-resistant prostate cancer, targets transactivation unit 5 of the androgen receptor

10.1021/acschembio.6b00182 · 2016 · External reference

EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer

10.1093/annonc/mdz244.065 · 2019 · External reference

Comprehensive in vitro characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal domain inhibitor

10.1158/1538-7445.am2021-1209 · 2021 · External reference

Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC)

10.1200/jco.2023.41.6_suppl.179 · 2023 · External reference

1813P Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results

10.1016/j.annonc.2023.09.2761 · 2023 · External reference

Treatment of prostate cancers and kennedy’s disease by PROTAC-androgen receptor degradation

10.1021/acsmedchemlett.9b00115 · 2019 · External reference

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC)

2022 · External reference

First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

10.1200/jco.2024.42.4_suppl.134 · 2024 · External reference

ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study

10.1200/jco.2024.42.16_suppl.5011 · 2024 · External reference

Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer

10.1016/j.annonc.2024.09.005 · 2024 · External reference

Bipolar androgen therapy (BAT): A patient’s guide

10.1002/pros.24328 · 2022 · External reference

Bipolar androgen therapy: When excess fuel extinguishes the fire

10.3390/biomedicines11072084 · 2023 · External reference

Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy

10.1016/j.ejca.2020.11.043 · 2021 · External reference

A multicohort open-label phase II trial of bipolar androgen therapy in men with metastatic castration-resistant prostate cancer (RESTORE): A comparison of post-abiraterone versus post-enzalutamide cohorts

10.1016/j.eururo.2020.06.042 · 2021 · External reference

TRANSFORMER: A randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer

10.1200/jco.20.02759 · 2021 · External reference

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review

2022 · External reference

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: A multicentre, randomised, open-label, phase 2, crossover trial

10.1016/s1470-2045(19)30688-6 · 2019 · External reference

Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients

10.1016/j.eururo.2014.06.045 · 2015 · External reference

DNA damage and transcription stress

10.1016/j.molcel.2023.11.014 · 2024 · External reference

The multifaceted roles of PARP1 in DNA repair and chromatin remodelling

10.1038/nrm.2017.53 · 2017 · External reference

The long tail of oncogenic drivers in prostate cancer

10.1038/s41588-018-0078-z · 2018 · External reference

Integrative clinical genomics of advanced prostate cancer

10.1016/j.cell.2015.05.001 · 2015 · External reference

Survival with olaparib in metastatic castration-resistant prostate cancer

10.1056/nejmoa2022485 · 2020 · External reference

First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States

10.1016/j.ctrv.2024.102726 · 2024 · External reference

Androgen receptor inhibitor-induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer

10.1126/scisignal.aam7479 · 2017 · External reference

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): Final prespecified overall survival results of a randomised, double-blind, phase 3 trial

10.1016/s1470-2045(23)00382-0 · 2023 · External reference

1601P First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)

10.1016/j.annonc.2024.08.1682 · 2024 · External reference

BRCAness revisited

10.1038/nrc.2015.21 · 2016 · External reference

DNA-repair defects and olaparib in metastatic prostate cancer

10.1056/nejmoa1506859 · 2015 · External reference

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): An open-label, phase 2 trial

10.1016/s1470-2045(21)00376-4 · 2021 · External reference

Microenvironmentally responsive chemotherapeutic prodrugs and CHEK2 inhibitors self-assembled micelles: Protecting fertility and enhancing chemotherapy

2023 · External reference

ATM-inhibitor AZD1390 is a radiosensitizer for breast cancer CNS metastasis

10.1158/1078-0432.ccr-23-0290 · 2023 · External reference

Effect of cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma: A phase 2 randomized clinical trial

10.1001/jamaoncol.2021.3441 · 2021 · External reference

Combination platinum-based and DNA damage response-targeting cancer therapy: Evolution and future directions

10.2174/0929867323666161214114948 · 2017 · External reference

PARP inhibitors combined with radiotherapy: Are we ready?

10.3389/fphar.2023.1234973 · 2023 · External reference

Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners

10.1007/s10555-021-09976-0 · 2021 · External reference

Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer

10.1200/jco.2016.69.1584 · 2017 · External reference

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial

10.1016/s1470-2045(14)70189-5 · 2014 · External reference

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: Case report of two patients

10.1186/s40425-017-0232-7 · 2017 · External reference

Final analysis of the Ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors

10.1016/j.eururo.2020.07.032 · 2020 · External reference

Pembrolizumab for advanced prostate adenocarcinoma: Findings of the KEYNOTE-028 study

10.1093/annonc/mdy232 · 2018 · External reference

Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study

10.1200/jco.19.01638 · 2020 · External reference

KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC)

10.1200/jco.2020.38.15_suppl.5543 · 2020 · External reference

Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: The randomized, open-label, phase III KEYLYNK-010 trial

10.1200/jco.23.00233 · 2023 · External reference

1771MO Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study

10.1016/j.annonc.2023.09.2721 · 2023 · External reference

Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study

2023 · External reference

690TiP a phase III, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX)

10.1016/j.annonc.2020.08.2084 · 2020 · External reference

Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from the phase II CheckMate 9KD trial

10.1016/j.ejca.2021.09.043 · 2022 · External reference

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: A randomized phase 3 trial

10.1038/s41591-021-01600-6 · 2022 · External reference

LBA67 Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study

10.1016/j.annonc.2024.08.2310 · 2024 · External reference

CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)

10.1093/annonc/mdz394.044 · 2019 · External reference

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment

10.1136/jitc-2021-002919 · 2021 · External reference

Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial

10.1002/pros.24110 · 2021 · External reference

Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial

10.1016/j.ccell.2020.08.007 · 2020 · External reference

Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial

10.1200/jco.2023.41.6_suppl.22 · 2023 · External reference

Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: An expression-based analysis

10.1038/pcan.2016.49 · 2017 · External reference

B7 score and T cell infiltration stratify immune status in prostate cancer

10.1136/jitc-2021-002455 · 2021 · External reference

Neoadjuvant enoblituzumab in localized prostate cancer: A single-arm, phase 2 trial

10.1038/s41591-023-02284-w · 2023 · External reference

A novel anti-B7-H3 × anti-CD3 bispecific antibody with potent antitumor activity

2022 · External reference

Targeting B7-H3 in prostate cancer: Preclinical proof of concept with MGC018, an investigational anti-B7-H3 antibody-drug conjugate

10.1158/1538-7445.am2022-330 · 2022 · External reference

1842TiP Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK)

10.1016/j.annonc.2023.09.2790 · 2023 · External reference

B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer

10.1038/s41420-023-01453-7 · 2023 · External reference

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: A first-in-human, first-in-class, open-label, phase 1 study

10.1016/s1470-2045(16)30565-4 · 2017 · External reference

Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer

10.1126/scitranslmed.aav0891 · 2019 · External reference

Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC)

2022 · External reference

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: A phase 1 trial

10.1038/s41591-022-01726-1 · 2022 · External reference

PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: A phase 1 trial

10.1038/s41591-024-02979-8 · 2024 · External reference

EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors

10.1126/sciadv.adg9721 · 2023 · External reference

Prospect of prostate cancer treatment: Armed CAR-T or combination therapy

10.3390/cancers14040967 · 2022 · External reference

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

10.1056/nejmoa1001294 · 2010 · External reference

A phase 3 trial of GVAX immunotherapy for prostate cancer vs. docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC)

2009 · External reference

Efficacy and safety of autologous dendritic cell-based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: The VIABLE phase 3 randomized clinical trial

10.1001/jamaoncol.2021.7298 · 2022 · External reference

Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer

10.1200/jco.18.02031 · 2019 · External reference

A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel

10.3892/or.2020.7847 · 2021 · External reference

PD-1 or PD-L1 blockade restores antitumor efficacy following SSX2 epitope-modified DNA vaccine immunization

10.1158/2326-6066.cir-14-0206 · 2015 · External reference

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

10.1136/jitc-2021-004198 · 2022 · External reference

High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors

10.1186/s40425-018-0479-7 · 2018 · External reference

Cancer-associated fibroblast heterogeneity, activation and function: Implications for prostate cancer

10.3390/biom13010067 · 2022 · External reference

Myeloid-derived suppressor cells as key players and promising therapy targets in prostate cancer

10.3389/fonc.2022.862416 · 2022 · External reference

Decrease in CD8+ lymphocyte number and altered cytokine profile in human prostate cancer

2011 · External reference

Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression

10.1007/s00262-015-1752-y · 2015 · External reference

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer

10.1158/0008-5472.can-11-1417 · 2011 · External reference

Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy

10.1002/pros.21004 · 2009 · External reference

Distinct response to platinum-based chemotherapy among patients with metastatic castration-resistant prostate cancer harboring alterations in genes involved in homologous recombination

10.1097/ju.0000000000001819 · 2021 · External reference

Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations

10.1200/po.19.00346 · 2020 · External reference

Palbociclib and letrozole in advanced breast cancer

10.1056/nejmoa1607303 · 2016 · External reference

AR, the cell cycle, and prostate cancer

10.1621/nrs.06001 · 2008 · External reference

The strange case of CDK4/6 inhibitors: mechanisms, resistance, and combination strategies

10.1016/j.trecan.2016.11.006 · 2017 · External reference

A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone-sensitive prostate cancer

10.1158/1078-0432.ccr-21-0024 · 2021 · External reference

Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: A study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)

10.1136/bmjopen-2019-033667 · 2020 · External reference

A phase Ib/II study of the CDK4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer

10.1158/1078-0432.ccr-21-4302 · 2022 · External reference

Cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with ralaniten analogs for the treatment of androgen receptor-positive prostate and breast cancers

10.1158/1535-7163.mct-21-0411 · 2022 · External reference

Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer

10.1016/s1470-2045(23)00676-9 · 2024 · External reference

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

10.1186/s12943-023-01827-6 · 2023 · External reference

Recent advances in targeted strategies for triple-negative breast cancer

10.1186/s13045-023-01497-3 · 2023 · External reference

Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer

10.1038/s41416-024-02614-w · 2024 · External reference

Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss

10.1158/1078-0432.ccr-18-0981 · 2019 · External reference

Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy

10.1093/jnci/djv171 · 2015 · External reference

Cancer epigenetics: From mechanism to therapy

10.1016/j.cell.2012.06.013 · 2012 · External reference

Prostate cancer reactivates developmental epigenomic programs during metastatic progression

10.1038/s41588-020-0664-8 · 2020 · External reference

Global levels of histone modifications predict prostate cancer recurrence

10.1002/pros.21038 · 2010 · External reference

Histone modifications and chromatin organization in prostate cancer

10.2217/epi.10.31 · 2010 · External reference

The polycomb group protein EZH2 is involved in progression of prostate cancer

10.1038/nature01075 · 2002 · External reference

N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer

10.1016/j.ccell.2016.09.005 · 2016 · External reference

LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription

10.1038/nature04020 · 2005 · External reference

Selective inhibition of tumor oncogenes by disruption of super-enhancers

10.1016/j.cell.2013.03.036 · 2013 · External reference

Super-enhancers in the control of cell identity and disease

10.1016/j.cell.2013.09.053 · 2013 · External reference

Targeting the p300/CBP axis in lethal prostate cancer

10.1158/2159-8290.cd-20-0751 · 2021 · External reference

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

10.1038/nature24028 · 2017 · External reference

The role of histone deacetylases (HDACs) in human cancer

10.1016/j.molonc.2007.01.001 · 2007 · External reference

Understanding failure and improving treatment using HDAC inhibitors for prostate cancer

10.3390/biomedicines8020022 · 2020 · External reference

Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer

10.1016/j.celrep.2017.05.049 · 2017 · External reference

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

10.1038/nature13229 · 2014 · External reference

Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors

10.1093/jncics/pkz093 · 2020 · External reference

Cleavable linkers in antibody-drug conjugates

10.1039/c8cs00676h · 2019 · External reference

Exploring the next generation of antibody-drug conjugates

10.1038/s41571-023-00850-2 · 2024 · External reference

Antibody-drug conjugates come of age in oncology

10.1038/s41573-023-00709-2 · 2023 · External reference

PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study

10.1002/pros.23922 · 2020 · External reference

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer

10.1016/j.urolonc.2016.07.005 · 2016 · External reference

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: Final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

10.1016/j.annonc.2021.03.005 · 2021 · External reference

Single-arm, phase II study to evaluate the safety and efficacy of sacituzumab govitecan in patients with metastatic castration-resistant prostate cancer who have progressed on second generation AR-directed therapy

10.1200/jco.2020.38.6_suppl.tps251 · 2020 · External reference

Imaging patients with metastatic castration-resistant prostate cancer using (89)Zr-DFO-MSTP2109A anti-STEAP1 antibody

10.2967/jnumed.118.222844 · 2019 · External reference

Phase I study of DSTP3086S, an antibody-drug conjugate targeting six-transmembrane epithelial antigen of prostate 1, in metastatic castration-resistant prostate cancer

10.1200/jco.19.00646 · 2019 · External reference

Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer

10.3390/cancers15051621 · 2023 · External reference

Notch pathway inhibition using PF-03084014, a γ-secretase inhibitor (GSI), enhances the antitumor effect of docetaxel in prostate cancer

10.1158/1078-0432.ccr-15-0242 · 2015 · External reference

Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy

10.18632/oncotarget.22115 · 2017 · External reference

Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model

10.1371/journal.pone.0184418 · 2017 · External reference

Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin

10.1002/cam4.675 · 2016 · External reference

Delivery of curcumin nanoliposomes using surface modified with CD133 aptamers for prostate cancer

10.2147/dddt.s210949 · 2019 · External reference